One approach to understanding how tissue-specific cancers emerge is to determine the requirements for “reprograming” such neoplastic cells back to their developmentally normal primordial pre-malignant epiblast-like pluripotent state and then scrutinizing their spontaneous reconversion to a neoplasm, perhaps rendering salient the earliest pivotal oncogenic pathway(s) (before other aberrations accumulate in the adult tumor). For the prototypical malignancy anaplastic thyroid carcinoma (ATC), we found that tonic RAS reduction was obligatory for reprogramming cancer cells to a normal epiblast-emulating cells, confirmed by changes in their transcriptomic and epigenetic profiles, loss of neoplastic behavior, and ability to derive normal somatic cells from their “epiblast organoids.” Without such suppression, ATCs re-emerged from the clones. Hence, for ATC, RAS inhibition was its “reprogram enablement” (RE) factor. Each cancer likely has its own RE factor; identifying it may illuminate pre-malignant risk markers, better classifications, therapeutic targets, and tissue-specification of a previously pluripotent, now neoplastic, cell.
Microglia migrate from the yolk sac and populate the developing brain. How microglia expand rapidly to meet the microglial demand in fast-expanding human fetal brains remains uncharted. Using thick sections in 5−22–gestational week (gw) brains and super-resolution scanning, we identified a large proliferative microglial aggregate (2.129 mm2) near the lateral ganglionic eminence (>12.5 gw), expanding in Down’s syndrome (DS) (4.767 mm2) and Edwards syndrome (ES) (3.437 mm2) fetal brains. Ki67+ microglia within the aggregates accounted for 26.65% (DS: 38.9%; ES: 46.3%) compared with 6.32% (DS: 6.01%; ES: 5.2%) in scattered microglia. This aggregate region contained a distinct microglial population characterized by the absence of phagocytic structures and complex processes, high CSF-1R expression, abundant IL-34+ cells, and some SPP1+ bipolar microglia. We termed this structure the secondary microglial formation center (SMFC). Chimeric microglia–human cortical organoids recapitulated the SMFC in an IL-34– and CSF-1R–dependent manner, indicating that the human SMFC may compensate for the microglial shortage during the fastest expansion period.
The MAPK-ERK1/2 pathway plays a crucial role in neurodevelopment during embryogenesis, and the hyperactivation of this signaling cascade serves as a pathological hallmark for various neurodevelopmental disorders. Germline variants in TRAF7 , encoding a RING-type E3 ubiquitin ligase, are genetically associated with cardiac, facial, and digital anomalies with developmental delay (CAFDADD) syndrome; however, the downstream substrates of TRAF7 and the precise mechanism driving neurodevelopmental defects remain enigmatic. Here, we established a Traf7R654Q/+ knock-in mouse model and patient-specific induced pluripotent stem cell (iPSC)–derived human cortical organoids (hCOs) carrying the recurrent TRAF7R655Q mutation. Heterozygous Traf7R654Q/+ mice exhibited remarkable growth retardation, skeletal abnormalities, and neurobehavioral deficits, whereas mutant hCOs displayed early cortical neurogenesis defects, characterized by premature neural differentiation and a depleted progenitor pool. Mechanistically, biochemical analyses revealed that TRAF7 interacts with KRAS and NRAS to promote their polyubiquitination and subsequent proteasomal degradation, maintaining physiological homeostatic control over the downstream MAPK cascade. CAFDADD-associated TRAF7 variants exert a dominant-negative effect, disrupting WT protein function and causing the posttranslational accumulation of KRAS and NRAS, which fundamentally drives constitutive MAPK-ERK1/2 pathway hyperactivation. Notably, pharmacological inhibition of MEK1/2 with selumetinib suppressed ERK1/2 hyperactivation, partially mitigated aberrant neuroepithelial morphology and neural differentiation in TRAF7R655Q/+ hCOs, and improved brain-to-body weight ratios in Traf7R654Q/+ mice. Together, our findings identify TRAF7 as a critical posttranslational regulator of RAS proteostasis during development and uncover a pivotal mechanistic link between impaired RAS ubiquitination and CAFDADD pathogenesis, providing preliminary clinical-front evidence for targeting the MAPK pathway to manage ongoing developmental deficits in TRAF7-associated disorders.
Yolk sac-derived microglia migrate and populate the brain during development, constituting 10−15% of the total brain cells. The human brain is the largest and most complex brain with the highest cognitive capacity among all species. Therefore, the limitations of rodent brain studies in interpreting the human brain are evident. By co-immunostaining microglia in 50 µm fetal brain sections from 7.5 to 16 gestational weeks (gw) and combining high-resolution scanning, we identified a highly proliferative microglia aggregate (0.108−2.129 mm 2 ) that expanded in Down’s Syndrome fetal brain (4.168 mm 2 ) and was located near the ganglion eminence, in which Ki67 + microglia accounted for 23.4% of total microglia compared to 6.3% in other brain regions. The microglia in the aggregates lack phagocytic bulbs, membrane ruffles, and long/branching processes compared to microglia in other brain regions. Introducing human microglia into cortical organoids, but not macrophages, replicated proliferative microglial aggregates on the brain organoid surface and sufficiently penetrated deeper regions of the cortical organoids. Penetrating microglia display phagocytic capacity, enhance immunity, and accelerate the maturation of brain organoids. The large proliferative microglial aggregate may be a unique secondary microglial formation center in the human fetal brain to compensate for the enormous microglial demands during brain expansion.